Drug approval boosts Aventis bid defence
Aventis blosted its defence against Sanofi-Synthelabo's hostile takeover bid with news that its application to launch Exubera, an inhaled form of insulin, had been accepted by European drug
Aventis blosted its defence against Sanofi-Synthelabo's hostile takeover bid with news that its application to launch Exubera, an inhaled form of insulin, had been accepted by European drug